Pha_Blogg-2010_Markku_900x506px

“Improved workflows are the key to meeting the demands of modern healthcare.”

Hello Markku Matkoski, Development Manager at Pharmacolog. Tell us about your background and why you’ve chosen this field of work?

Hi there! I’ve been engaged in product development in the field of radiation oncology since the early nineties. My aspiration and commitment has always been to help MDs, specialists, and other staff yield better outcomes for patients. I’ve done this during the past few decades in different capacities and roles, from working as a software developer, to being an architect giving guidance to organizations, to directing teams in achieving results in early exploratory projects and product development. I’m a strong believer in agile methodologies paired together with expertise, enabling us to find the best path forward in product development.

My aspiration and commitment has always been to help MDs, specialists, and other staff yield better outcomes for patients.

Pharmacolog’s two latest product concepts, WasteLog™ and PrepLog™, address drug control in different integrated environments. What are the main benefits of these products?

Both applications answer important questions in modern healthcare workflows—before and after administration of drugs. With PrepLog you can ensure that you are administering the right drug with correct concentration to yield maximum outcome for patients, and with WasteLog you verify that patients have received the right drug in addition to diversion control.

What is the biggest challenge when it comes to increasing medication efficacy and safety today?

It seems that the number of preparations is increasing over time with the same or limited resources. Improved workflows through automation and integrations are the key to meeting the demands of modern healthcare. While performance has to increase, we must also make sure to verify results in order to have an efficient and safe drug control process.

What are your thoughts on this topic? Feel free to contact me or continue the discussion on our Facebook and LinkedIn pages.

 

Photo: Göran Ekeberg